NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $21.83 -0.37 (-1.67%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$21.86 +0.03 (+0.11%) As of 08:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Viridian Therapeutics Stock (NASDAQ:VRDN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Viridian Therapeutics alerts:Sign Up Key Stats Today's Range$21.40▼$22.1450-Day Range$18.03▼$24.8052-Week Range$13.18▼$34.29Volume1.21 million shsAverage Volume1.13 million shsMarket Capitalization$2.47 billionP/E RatioN/ADividend YieldN/APrice Target$38.54Consensus RatingModerate Buy Company Overview Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases involving the immune system. The company’s primary focus is thyroid eye disease (TED), an autoimmune disorder that can cause inflammation, pain, swelling and vision-related complications. Viridian’s lead programs target the insulin-like growth factor 1 receptor (IGF-1R), a pathway associated with TED. Its pipeline has included investigational therapies such as veligrotug (VRDN-001), an intravenous antibody designed to block IGF-1R, and subcutaneous formulations intended to provide more convenient administration. The company is also evaluating additional pipeline candidates for potential use in TED and other immune-mediated conditions. Based in the United States, Viridian conducts research and clinical development activities through collaborations and clinical programs that may involve multiple geographic regions. Its therapies remain investigational unless approved by applicable regulatory authorities, and the company’s development programs are subject to clinical, regulatory and commercial risks.AI Generated. May Contain Errors. Read More Viridian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreVRDN MarketRank™: Viridian Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 420th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialViridian Therapeutics has a consensus price target of $38.54, representing about 76.5% upside from its current price of $21.83.Amount of Analyst CoverageViridian Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Viridian Therapeutics are expected to grow in the coming year, from ($4.07) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.65% of the float of Viridian Therapeutics has been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 16.55, which indicates bearish sentiment.Change versus previous monthShort interest in Viridian Therapeutics has recently increased by 2.55%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.07 News SentimentViridian Therapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Viridian Therapeutics this week, compared to 5 articles on an average week.Search Interest6 people have searched for VRDN on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows4 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $348,194.00 in company stock.Percentage Held by Insiders2.40% of the stock of Viridian Therapeutics is held by insiders.Percentage Held by InstitutionsViridian Therapeutics has minimal institutional ownership at this time.Read more about Viridian Therapeutics' insider trading history. Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRDN Stock News HeadlinesViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 10, 2026 | americanbankingnews.comViridian Intersects Over 50 Metres of Mineralization from Surface at Kraken MainSeptember 8, 2026 | globenewswire.com$20,000 gold before year end?President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.September 16 at 1:00 AM | Stansberry Research (Ad)Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare ConferenceSeptember 2, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)August 26, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)August 21, 2026 | theglobeandmail.comInsider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 SharesAugust 21, 2026 | insidertrades.comViridian Therapeutics Inc VRDNAugust 15, 2026 | morningstar.comMSee More Headlines VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $31.12 at the beginning of 2026. Since then, VRDN stock has decreased by 29.9% and is now trading at $21.83. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) announced its earnings results on Thursday, August, 6th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by $0.02. The company had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative trailing twelve-month return on equity of 72.97%. When did Viridian Therapeutics IPO? Viridian Therapeutics (VRDN) raised $9 million in an initial public offering (IPO) on Thursday, June 12th 2014. The company issued 850,000 shares at a price of $10.00-$12.00 per share. Who are Viridian Therapeutics' major shareholders? Top institutional shareholders of Viridian Therapeutics include Wellington Management Group LLP (2.76%), Parkman Healthcare Partners LLC (1.22%), Rice Hall James & Associates LLC (1.14%) and Elmind Capital LP (0.87%). Insiders that own company stock include Fairmount Funds Management Llc, Stephen F Mahoney, Thomas W Beetham and Jennifer Tousignant. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viridian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/06/2026Today9/16/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VRDN's financial health is in the Green zone, according to TradeSmith. VRDN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VRDN CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees252Year FoundedN/APrice Target and Rating Average Price Target for Viridian Therapeutics$38.54 High Price Target$61.00 Low Price Target$22.00 Potential Upside/Downside+76.5%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$342.60 million Net Margins-505.86% Pretax Margin-544.06% Return on Equity-72.97% Return on Assets-42.80% Debt Debt-to-Equity Ratio0.43 Current Ratio16.95 Quick Ratio16.95 Sales & Book Value Annual Sales$70.85 million Price / Sales34.91 Cash FlowN/A Price / Cash FlowN/A Book Value$6.18 per share Price / Book3.53Miscellaneous Outstanding Shares113,290,000Free Float110,573,000Market Cap$2.47 billion OptionableOptionable Beta0.97 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:VRDN) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersNNVC on Alert: FDA Validation and Outperform Rating!NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to...Equiscreen | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
